ValuEngine downgraded shares of ProPhase Labs, Inc. (NASDAQ:PRPH) from a hold rating to a sell rating in a research note issued to investors on Thursday.

Shares of ProPhase Labs (NASDAQ:PRPH) traded up 0.97% during mid-day trading on Thursday, reaching $2.09. The company had a trading volume of 489 shares. The company has a market capitalization of $33.79 million, a P/E ratio of 0.87 and a beta of 0.02. The firm has a 50-day moving average of $2.21 and a 200-day moving average of $2.08. ProPhase Labs has a 12-month low of $1.78 and a 12-month high of $2.45.

ProPhase Labs (NASDAQ:PRPH) last announced its quarterly earnings results on Friday, August 11th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $1.91 million for the quarter. ProPhase Labs had a net margin of 270.98% and a return on equity of 54.87%.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/10/08/valuengine-lowers-prophase-labs-inc-prph-to-sell.html.

ProPhase Labs announced that its Board of Directors has authorized a stock buyback plan on Tuesday, August 15th that permits the company to buyback 4,000,000 shares. This buyback authorization permits the company to reacquire shares of its stock through a tender offer. Shares buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

In related news, CFO Robert V. Cuddihy, Jr. sold 358,621 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $2.30, for a total transaction of $824,828.30. Following the completion of the sale, the chief financial officer now owns 132,703 shares of the company’s stock, valued at $305,216.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Braden Michael Leonard sold 1,695,305 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $2.30, for a total transaction of $3,899,201.50. The disclosure for this sale can be found here. Insiders have sold 2,423,255 shares of company stock valued at $5,573,487 in the last three months. 29.60% of the stock is owned by insiders.

ProPhase Labs Company Profile

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.